Hepato-gastroenterology · 2009
Significance of sucrose permeability test in detecting early gastric cancer and changes of permeability after endoscopic mucosal resection.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamaguchi Taketo, Shishido Tadayuki, Hara Tarou, Ohyama Nami, Sudo Kentaro, Nakamura Kazuyoshi, Denda Tadamichi, Ishihara Takeshi, Yokosuka Osamu, Nomura Fumio
Аннотация
BACKGROUND/AIMS: To evaluate the diagnostic value of sucrose permeability test (SPT) with special reference to early gastric cancer (EGC), and to assess the changes of urinary sucrose level after treatment of gastric damage: gastric ulcer (GU) or EGC.
METHODOLOGY: Ninety subjects were included in this study, that is; 18 patients with GU, 25 EGC, 17 advance gastric cancer (AGC), and 30 healthy volunteers (HV). SPT was conducted before treatment in all the subjects, and in 6 patients each with GU and EGC after treatment- proton pump inhibitor for GU and endoscopic mucosal resection for EGC. Diagnostic values were calculated based on cut-off values estimated from the ROC curves.
RESULTS: The mean amount of sucrose excreted into urine in HV, GU, EGC, and AGC was 50.8 +/- 28.0 mg, 225.9 +/- 201.1 mg, 170.2 +/- 86.4 mg, and 426.2 +/- 155.0 mg, respectively, showing significant differences between HV and gastric disease groups (p < 0.01). The sensitivity for detecting GU, EGC, and AGC was 94.4%, 88.0%, and 100%, respectively. Sucrose excretion in GU and EGC was significantly decreased after treatment (262.4 +/- 121.2 to 80.6 +/- 42.1, and 246.0 +/- 136.9 to 139.1 +/- 69.2, p < 0.05 and p < 0.001, respectively).
CONCLUSIONS: SPT was considered useful to detect not only GU or AGC but also EGC with a high sensitivity. A significant decrease of sucrose excretion was observed after treatment in EGC.
METHODOLOGY: Ninety subjects were included in this study, that is; 18 patients with GU, 25 EGC, 17 advance gastric cancer (AGC), and 30 healthy volunteers (HV). SPT was conducted before treatment in all the subjects, and in 6 patients each with GU and EGC after treatment- proton pump inhibitor for GU and endoscopic mucosal resection for EGC. Diagnostic values were calculated based on cut-off values estimated from the ROC curves.
RESULTS: The mean amount of sucrose excreted into urine in HV, GU, EGC, and AGC was 50.8 +/- 28.0 mg, 225.9 +/- 201.1 mg, 170.2 +/- 86.4 mg, and 426.2 +/- 155.0 mg, respectively, showing significant differences between HV and gastric disease groups (p < 0.01). The sensitivity for detecting GU, EGC, and AGC was 94.4%, 88.0%, and 100%, respectively. Sucrose excretion in GU and EGC was significantly decreased after treatment (262.4 +/- 121.2 to 80.6 +/- 42.1, and 246.0 +/- 136.9 to 139.1 +/- 69.2, p < 0.05 and p < 0.001, respectively).
CONCLUSIONS: SPT was considered useful to detect not only GU or AGC but also EGC with a high sensitivity. A significant decrease of sucrose excretion was observed after treatment in EGC.